AVIAN ENTEROIDS
20220389388 · 2022-12-08
Inventors
Cpc classification
C12N5/0062
CHEMISTRY; METALLURGY
C12N2533/90
CHEMISTRY; METALLURGY
International classification
C12M1/12
CHEMISTRY; METALLURGY
C12M3/06
CHEMISTRY; METALLURGY
Abstract
There is provided an in vitro three dimensional cell construct for use as a model of the avian intestine derived from avian intestinal tissue comprising avian cells organised into intestinal villi and crypts. Suitably the construct comprises an exterior surface that mimics the apical surface of a chicken intestine. Also provided are methods of making the cell construct and use of the construct as an in vitro intestinal model system to examine an agent including, but not limited to a microbe, a vaccine, a pharmaceutical, a feed additive, a toxin, a pre-biotic, post-biotic, pre pro post biotic, therapeutic, a cell, gene construct, protein, immune-modulator, an intestinal effector agent, a candidate intestinal effector agent, cell signalling inhibitor, or cell signalling activator.
Claims
1. An in vitro three dimensional cell construct for use as a model of the avian intestine derived from avian intestinal tissue comprising avian cells organised into intestinal villi and crypts.
2. The in vitro cell construct of claim 1 wherein the construct comprises a surface that mimics the apical surface of a chicken intestine.
3. The in vitro cell as claimed in claim 1 wherein the construct comprises an exterior surface that mimics the apical surface of a chicken intestine.
4. The in vitro cell construct as claimed in claim 1 wherein the cell construct is an enteroid.
5. The in vitro cell construct of claim 1 comprising (a) a core (b) an exterior comprising an apical epithelial cell surface.
6. A method of culturing an in vitro three dimensional cell construct comprising avian cells organised into intestinal villi and crypts, the method comprising the steps a) providing isolated cells from intestinal tissue from an avian to culture media to provide culture media with seeded cells, b) expanding the seeded cells floating in the culture media to form at least one enteroid.
7. The method of claim 6 wherein the method does not require providing an extracellular matrix.
8. The method of claim 6 wherein the isolated cells are isolated from avian intestinal villi or intestinal crypt.
9. The method of claim 6 wherein the isolated cells are seeded by floating in culture media, optionally wherein the media is a basic media composed of DMEM/F12 and B27 supplement.
10. A method of screening an agent for activity the method comprising the steps of a. providing at least one cell construct of claim 1, b. contacting said agent to the cell construct in vitro, c. determining the activity or effect of the agent on cells of the cell construct.
11. A device for use in the method of claim 6 wherein the device comprises: a. a microfluidic device comprising a chamber and at least a first channel in fluid communication with the chamber, b. a cell construct as claimed in claim 1, optionally c. growth media in the chamber.
12. A method of growing a cell construct of claim 1, the method comprising a. providing a device of claim 11, b. providing growth media in the chamber at first time point to promote growth of the cells.
13. Use of an in vitro three dimensional cell construct comprising avian cells organised into intestinal villi and crypts as claimed in claim 1 in at least one selected from a group comprising of: examining microbe interactions, culturing of microbes, vaccine and pharmaceutical development, feed additive screening, toxicology studies and developmental studies, screening of pre-biotics, screening of post-biotics, screening of pre pro post biotics, screening of an intestinal effector agent, screening of an candidate intestinal effector agent and regenerative medicine.
14. A method of determining the efficacy of one or more therapies for one or more medical conditions, diseases or disorders comprising the step of exposing one or more therapies to the cell construct of claim 1.
15. Use of an in vitro three dimensional cell construct comprising avian cells organised into intestinal villi and crypts as provided by claim 6 in at least one selected from a group comprising; examining microbe interactions, culturing of microbes, vaccine and pharmaceutical development, feed additive screening, toxicology studies and developmental studies, screening of pre-biotics, screening of post-biotics, screening of pre pro post biotics, screening of an intestinal effector agent, screening of an candidate intestinal effector agent and regenerative medicine.
16. A method of determining the efficacy of one or more therapies for one or more medical conditions, diseases or disorders comprising the step of exposing one or more therapies to the cell construct as provided by any of the methods of claim 6.
17. A method of claim 14, wherein the efficacy of the one or more therapies are monitored by assaying at least one of the cell barrier integrity, assaying the gene expression of one or more genes, assaying the protein levels and/or identity of one or more proteins and/or assaying the histology, assaying the immune response of the enteroid culture.
18. A method of claim 14 wherein the method further comprises the step of providing one or more microbes to a cell construct.
19. A method of providing an in vitro intestinal model system, the method comprising: exposing an enteroid of claim 1 or as provided by a method of claim 6 with an agent monitoring the response of the enteroid to the agent, wherein the response of the enteroid to the agent is a model of the avian intestine.
20. The method of claim 19 wherein an agent is selected from a group comprising; a microbe, a vaccine, a pharmaceutical, a feed additive, a toxin, a pre-biotic, post-biotic, pre pro post biotic, therapeutic, a cell, gene construct, protein, immune-modulator, an intestinal effector agent, a candidate intestinal effector agent, cell signalling inhibitor, or cell signalling activator.
Description
[0095] Embodiments of the present invention will now be described with reference to the accompanying figures by way of example only, in which
[0096]
[0097]
[0098]
[0099]
[0100]
[0101]
[0102]
[0103]
[0104]
[0105]
[0106]
[0107]
[0108]
DETAILED DESCRIPTION OF THE INVENTION
Examples
Example 1—Animals
[0109] Experiments were performed using ED18 to 9 week old Hy-Line Brown chickens (Gallus gal/us), ED17 CSF1R-eGFP transgenic chickens and 2 day old quail (Coturnix coturnix) obtained from the National Avian Research Facility, Edinburgh, UK. Five month old C57BL/6 mice were provided by the Biological Research Facility, University of Edinburgh, UK. All animals were housed in premises licensed under a UK Home Office Establishment License in full compliance with the requirements of the Animals (Scientific Procedures) Act 1986 and with approval from The Roslin Institute Animal Welfare Ethics Review Board.
Example 2—Isolation of Avian Intestinal Stem Cells Containing Tissue
[0110] The small intestine was removed post-mortem, cut open longitudinally then into 5 mm sections and collected into Ca.sup.2+- and Mg.sup.2+-free Phosphate-buffered saline (PBS) and washed. The tissue was digested in Dulbecco's Modified Eagle's Medium (DMEM) (Thermo Fisher Scientific) with 0.2 mg/mL Collagenase from Clostridium histolyticum Type IA (Merck) at 37° C. The tube was shaken vigorously, tissue allowed to settle then supernatant collected. These steps were repeated to generate 4 fractions. Fractions were centrifuged at 100×g for 4 min and tissue integrity assessed. The crypts/villi were counted and resuspended in FOM at ˜200/mL; Advanced DMEM/F12 (Thermo Fisher Scientific) supplemented with 10 mM HEPES (Thermo Fisher Scientific), 2 mM L-Glutamine (Thermo Fisher Scientific), 50 U/mL Penicillin/Streptomycin (Merck) and 2% B27 supplement (50×; Thermo Fisher Scientific). Where indicated the enteroid cultures were supplemented with 25 ng/mL EGF (Prepotech), 25 ng/mL Noggin (Enzo Life Sciences), 250 ng/mL R-spondin (R&D Systems), 100 mM Y-27632 (Cambridge Bioscience), 100 mM SB202190 (Enzo Life Sciences) and 5 mM LY2157299 (Cambridge Bioscience). Differentiation of avian enteroids occurred at 37° C., 5% CO.sub.2 with media changed every 2 days. For duodenal, jejunal, caecal and quail enteroids the isolation and culture protocols were kept the same.
[0111] To seed chicken intestinal crypts/villi in Matrigel (Corning), the isolated material was resuspended in equal volumes of FOM and ice-cold Matrigel to allow for 50 per 50 μL and cultured as described for mouse intestinal crypts, using FOM instead of Intesticult medium (Stemcell Technologies).
Example 3—Infection of Organoids
[0112] Infection of Enteroids with Eimeria tenella Sporozoites
[0113] Frozen purified Eimeria tenella sporozoites were washed in warm DMEM and labelled with PKH67 Green Fluorescent Cell Linker kit (Sigma-Aldrich) according to manufacturer's protocol. ˜5×10.sup.4 sporozoites were added to each well containing fifty 2 day old chicken enteroids. These were incubated at 37° C., 5% CO.sub.2. Fresh caecal enteroids, cultured for 2 days, were added to the cultures at 4 and 6 dpi to provide fresh epithelial cells for the merozoite stages. Enteroids were collected for analysis at 1, 2, 4, 7 and 9 dpi.
Infection of Enteroids with Salmonella Typhimurium
[0114] Salmonella enterica subspecies enterica serovar Typhimurium strain 4/74 carrying a chromosomal pFVP25.1::gfp fusion linked to the naladixic acid resistance gene was utilised for infections of the chicken enteroids and compared to a defined mutant, ST4/74 nal.sup.R ΔprgH::kan. This prgH mutant is confirmed to have reduced Type 3 secretion by analysing secretion of SipC, a Salmonella type III secretion system effector protein, and was also transformed with the plasmid pFVP25.1 which constitutively expresses GFP. Strains were cultured overnight in Luria-Bertani (LB) broth with 50 μg/mL kanamycin (not used for wild-type ST4/74 nal.sup.R), 50 μg/mL ampicillin and 20 μg/mL naladixic acid at 37° C. Wells containing 50 enteroids were inoculated with 5×10.sup.4 bacteria in antibiotic-free FOM and incubated statically at 37° C., 5% CO.sub.2 before samples were collected at 0.5 and 4 hpi for analysis. Bacterial replication was measured by incubating enteroids with the Salmonella strains at 37° C., 5% CO.sub.2 for 1 h, then high-dose gentamicin (50 μg/mL) was added to the wells for 30 min. Enteroids were washed and incubated with low-dose gentamicin (10 μg/mL) added to FOM (without Penicillin/Streptomycin). Enteroids were collected at 0, 3 and 8 h post high-dose gentamicin treatment and disrupted using steel beads in a Tissue-Lyser. Serial dilutions were plated on naladixic acid containing LB agar in duplicate and incubated at 37° C. overnight.
Infection of Enterioids with Influenza Virus A
[0115] Fifty enteroids were incubated with 2×10.sup.7 PFU H1N1 virus (A/Puerto Rica/8/34 (PR8) in DMEM supplemented with 50 U/mL Penicillin/Streptomycin and 50× v/v B27 at 37° C., 5% CO.sub.2 for 1 h. Control cultures either had PBS or allantoic fluid from uninfected chicken eggs added to the media. The enteroids were then washed and reseeded in DMEM media supplemented with 2 μg/mL TPCK-trypsin and collected at 48 hpi for analysis. Supernatants were harvested at 0 and 48 h post incubation and titrated by plaque assay on MDCK cells.
Example 4
[0116] To determine the structure and composition of the cell constructs provided, a number of methods were utilised.
Transmission Electron Microscopy (TEM)
[0117] Enteroids were fixed in 3.0% glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.3, for 2 hours and processed as described as would be known in the art. Ultra-thin sections (60 nm) were stained in uranyl acetate and lead citrate and imaged using a JEOL JEM-1400 Plus TEM. Images were analysed using ImageJ (Fiji).
Whole Mount and Immunohistochemical (IHC) Staining
[0118] Details of the sources, clone numbers and concentrations of the primary and secondary antibodies used for IHC are provided in Table 1. Enteroids were fixed with 4% paraformaldehyde then blocked with 5% v/v goat serum in permeabilisation solution (0.5% v/v bovine serum albumin and 0.1% v/v Saponin in PBS) and stained with primary and secondary antibodies at 4° C. DNA was stained with 4′, 6-diamidino-2-phenylindole (DAPI; Thermo Fisher Scientific) and, where indicated, F-actin was visualised with Alexa Fluor conjugated Phalloidin (Thermo Fisher Scientific). Enteroids were then mounted in ProLong® Diamond Antifade Mountant (Thermo Fisher Scientific). Isotype and negative controls were prepared for each staining.
[0119] Intestinal tissue was snap frozen in liquid nitrogen, 10 μm sections were prepared on a Leica Cryostat CM1900 and mounted on Superfrost Plus slides (Thermo Fisher Scientific). Tissues were fixed in 50% methanol then blocked and stained as described for staining of whole mount enteroids.
TABLE-US-00001 TABLE 1 Primary antibodies used for immunohistochemistry. Antibody Catalog Target details Clone number Dilution Mucin 5AC Mouse anti- 45M1 Ab212636 20 μg/ml mucin 5AC .sup.a Lysozyme C Rabbit anti- polyclonal Ab391 20 μg/ml lysozyme .sup.a Chromogranin Rabbit anti- polyclonal 20085 1.3 μg/ml A[SP1] chromogranin A .sup.b Sox9 [phospho Rabbit anti- polyclonal Ab59252 2 μg/ml S181] SOX9 .sup.a Villin Mouse anti- 1D2C3 Sc-58897 4 μg/ml villin .sup.c E-Cadherin Mouse anti-E- 36/E- 610181 5 μg/ml Cadherin .sup.d Cadherin ZO-1 tight Rabbit anti- polyclonal Ab216880 10 μg/ml junction ZO1 .sup.a protein Virus Rabbit anti- polyclonal n/a 1:1000 nucleoprotein NP .sup.e CD45 Mouse anti- AV53 n/a 1:100 CD45.sup.f ChB6 Mouse anti- AV20 839502 2 μg/ml Bu-1.sup.g CD3 Mouse anti- CT-3 820009 2 μg/ml CD3.sup.h
RNA Isolation and Sequencing
[0120] Enteroids from three cultures were collected at 0, 3 and 7 days of culture, lysed in RLT buffer (Qiagen) containing 10 μg/mL 2-mercaptoethanol (Sigma-Aldrich) and homogenised using Qiashredder columns (Qiagen). Each culture (biological replicate) arose from 3 pooled embryos. Two duplicate plates were cultured for each biological replicate, and samples were taken from each plate as technical replicates. RNA was extracted using the RNeasy mini kit (Qiagen) according to the manufacturer's protocol including DNase I treatment. The RNA quality and concentration was assessed using D1000 Screentape Agilent System (Agilent Technologies) then stored at −80° C. Libraries were prepared and sequenced on Illumina Novaseq 6000 by using 150-bp paired-end sequencing. Obtained reads were trimmed for quality and to remove adaptor sequences using Cutadapt. Reads after trimming were required to have a minimum length of 50 bases. Paired-end reads from Illumina sequencing were aligned to the Gallus gallus genome (Gallus_gallus-5.0) using STAR. The annotation used for counting was the standard GTF-format annotation for that reference (annotation version 91). Raw counts for each annotated gene were obtained using the featureCounts software (version 1.5.2). Differential gene expression analysis was performed within the Bioconductor edgeR package (version 3.16.5). Comparison of the embryonic enteroid transcriptome at 0, 3 and 7 days post cultivation revealed that there were no differentially expressed genes between the technical replicates (FDR<0.05), demonstrating the consistency and reproducibility of the enteroid system. The sumTechReps function in EdgeR was used to merge technical replicates. All subsequent steps were performed on the merged samples. The raw counts table was filtered to remove genes consisting predominantly of near-zero counts, filtering on counts per million (CPM) to avoid artefacts due to library depth. Statistical assessment of differential expression was carried out with the likelihood-ratio test. Differentially expressed genes were defined as those with FDR<0.05 and log FC>2. Heatmaps were constructed in R using the pheatmap package (v. 1.0.10).
[0121] Development of chicken enteroids after villi or crypt isolation using a Matrigel-based culture system resulted in poor representations of the in vivo chicken intestine (
Floating chicken enteroids demonstrate a unique ‘inside-out’ phenotype
[0122] Self-organising chicken and mammalian enteroids embedded in Matrigel demonstrate a single sheet of epithelial cells that are polarized so the microvilli surface is facing into a central lumen. In contrast, fluorescent staining of the embryonic floating chicken enteroids of the invention at 2 and 7 days after cultivation showed their epithelial cells had an atypical reversed polarity (
[0123] To confirm the ‘inside-out’ phenomenon was unique to floating enteroids, the isolated embryonic chicken villi were seeded into Matrigel domes and imaged at 2 and 7 days of culture (
[0124] Similar staining was performed on 2 and 7 day chicken enteroids derived from 9 week old birds to investigate if the reverse polarity was related to the age and type of progenitor enteroid tissue (
[0125] In order to explore whether the development of ‘inside-out’ enteroids from floating crypts/villi was a species-specific phenomenon, F-actin staining of floating enteroids from 2 day old quail was performed at 2 and 7 days of culture (
[0126] The inventors then expanded the range of species analysed to explore the phenotypic plasticity of mammalian intestinal crypts in a liquid environment. Mouse crypts (
Floating Chicken Enteroids Reproduce the Cellular Diversity of the Intestinal Epithelium In Vivo
[0127] To investigate whether the multilobulated floating chicken enteroids displayed the array and of cell types that would be expected in vivo, immunofluorescent staining and TEM were performed at various time-points from isolation to 7 days of enteroid culture and compared with embryonic and immunologically mature chicken jejunal tissue sections.
[0128] In human and mouse small intestinal epithelium, lysozyme C is synthesized and secreted by crypt dwelling Paneth cells, in the embryonic chicken small intestine and floating chicken enteroids, lysozyme C-expressing epithelial cells were observed scattered throughout the epithelium (
[0129] The transcriptional profile of embryonic enteroids at 0, 3 and 7 days post cultivation suggested expression of gene sets characteristically associated with mammalian Paneth cells, enterocytes, goblet cells and enteroendocrine cells (
[0130] In order to provide site-specific models for in vitro infection studies, differentiated chicken duodenal, jejunal and caecal enteroids were individually prepared (
Example 5
Chicken Intestinal Organoids are Susceptible to Infection by Bacteria, Eukaryotic Parasites and Viruses
[0131] Once an in vitro chicken enteroid culture system and its reversed polarisation had been established, the inventors tested if they could be infected by different classes of pathogens. The ‘inside-out’ phenotype facilitated uncomplicated infection studies by simply adding microorganisms to the media, using a range of important avian and zoonotic pathogens. Enteroids were incubated for 4 h with either a wild-type S. Typhimurium strain or a non-invasive mutant strain, defective in the Salmonella pathogenicity island 1 (SPI1)-encoded T3SS. S. Typhimurium uses effector proteins translocated by the SPI1 T3SS to induce host-cell actin remodelling on the apical surface of polarized epithelial cells. These membrane ‘ruffles’ are a well-characterised feature of Salmonella virulence, promoting internalization of the pathogen by non-phagocytic cells. After 30 min of wild-type S. Typhimurium incubation with enteroids, the bacteria were visualised in contact with the apical epithelial surface. At 4 hours post infection (hpi), dense actin rings surrounded individual bacteria (
[0132] Influenza A Viruses that affect poultry are primarily respiratory pathogens, but will readily infect the intestines of many avian species. Invasion of PR8 (a mouse adapted H1N1 labstrain) into epithelial cells is the basis for virus replication and this process was confirmed in the chicken enteroids by confocal microscopy. Expression of viral nucleoprotein (NP) was detected within the epithelium of the enteroids at 24 hpi (
[0133] The use of avian enteroids as models for viral infection is particularly advantageous as it provides for a model to study influenza infection. Some Influenza A virus strains survive and replicate in the intestine of waterfowls, spreading through fecal matter to cause an epidemic potential. Enteroids as discussed herein, for example chicken enteroids are considered to provide a representative experimental model for studying the gastrointestinal interactions of avian influenza virus in waterfowl. The inventors have detected H1N1 virus non-structural protein, NP, by immunofluorescence at 48 hpi throughout the organoid structures and confirmed replication through plaque assays, demonstrating PR8 successfully infected the enteroids and confirming these are capable models to recreate viral infection of the avian intestinal mucosa.
Successful Invasion of the E. tenella Sporozoites in Chicken Enteroids
[0134] The apicomplexan protozoa of the genus Eimeria are one of the major parasitic diseases of poultry. Following oral infection in vivo, the E. tenella sporozoites enter the caecal epithelial cells, migrate through the lamina propria to undergo multiple rounds of asexual multiplication at the base of the crypts, before eventually undergoing sexual multiplication. Since each developmental stage of Eimeria harbours a distinct number of parasitic divisions, the inventors used a combination of brightfield and fluorescence microscopy to determine whether the enteroid cultures could support parasite replication. In order to visualise the parasites, E. tenella sporozoites were stained with a fluorescent cell-membrane tracking dye, PKH67.
[0135] As shown in
Example 6
Epithelial Barrier Integrity and Cell Stress
[0136] The innermost layer of the intestinal luminal surface consists of a single cell thick epithelial lining which acts as a barrier, preventing the entry of harmful molecules and microbes while still allowing the selective passage of dietary nutrients, ions, and water. Tight junction proteins together with adherens junctions and desmosomes are essential gut epithelia barrier components which maintain physiological homeostasis. By immunostaining for two major cell-adhesion molecules and using TEM, the inventors demonstrated the presence of these junctions in chicken enteroids. Desmosomes and tight junctions (
[0137] Transcriptional analysis demonstrated that the enteroids expressed a large range of genes encoding components of mammalian focal adhesions, tight junctions, gap junctions, adherens junctions and desmosomes (
[0138] Floating chicken enteroids were found to develop and survive for a period of time. Without wishing to be bound by theory, it is considered that, for example with use of B27 media without additional exogenous growth and/or inhibitory factors, the cells in the isolated tissue and/or accompanying fibroblasts appear to initially supply the required factors for stem cell proliferation and propagation of intestinal epithelium. A unique feature of avian enteroids grown floating in culture is their ‘inside-out’ conformation, with the apical brush border facing the media. Intestinal stem cells contained within avian embryonic villi or mature crypts successfully self-organise to form enteroids with 3D multilobulated structures that mimic the in vivo architecture and differentiated cell-types of the in vitro avian intestinal epithelium.
[0139] Floating avian crypts rapidly orientate themselves so their basal epithelial surface rests on a dense central core of cells, thereby re-establishing integrin signalling. This positional change was not visualised in murine cultures and so the inventors consider this is an avian-specific phenomenon.
[0140] The inventors have demonstrated that the chicken enteroid in vitro model is closely akin to the in vivo intestine and will therefore provide more valuable data than single cell cultures as well as providing cost and ethical benefits to the poultry industry by avoiding the need for in vivo studies. The classical matrix-embedded enteroid, as determined for mammalian enteroids, possesses an internal lumen which proves limiting for host-pathogen studies where fragmenting the enteroids cannot guarantee the route of pathogen entry, and microinjections and monolayers add increasing layers of complexity and cost to the infection process. The novel externally accessible epithelial surface of the chicken enteroids allows for uncomplicated replication of the natural infection process.
[0141] The method to isolate crypts and derive differentiated enteroids with an accessible epithelial layer from the chicken small and large intestine as discussed herein allows for inexpensive and uncomplicated techniques to study host-pathogen interactions, pharmaceutical, nutritional, food additive and developmental studies.
[0142] As these enteroids reflect the 3D architecture and cellular composition of their in vivo counterparts they provide an effective in vitro model of the chicken intestinal epithelium.
Example 7—Immune Cell Component of Enteroid
[0143] Since embryonic enteroids develop from intestinal villi the inventors determined whether they also contained immune cells derived from the intestinal lamina propria. Using immunohistochemistry the inventors identified CD45+ leukocytes scattered throughout the central cell-dense core of the enteroids (
[0144] Further transcriptional analysis of mRNA from floating enteroids showed the expression of gene sets encoding various leukocytes of the mammalian enteric immune system (
Uses of 3D Enteroids to Study Immune Responses after Interaction with Micro-Organisms and Pharmaceutical/Vaccine Components
[0145] The inventors have determined methods to successfully differentiate self-organising, extensively budding avian enteroids that mimic the in vivo architecture and eplithelial characteristics of avian intestine without the use of a gel scaffold. Strikingly, the avian enteroids grown floating in culture adopt an “inside-out” confirmation, witht the apical brush border facing the media. Additionally these enteroids comprise leukocytes that makes them a useful, natural epithelial-leukocyte co-culture model.
[0146] An example of the tests conducted on the enteroids provided by the invention which show that these are useful as a model system is discussed below.
[0147] Incubation of 3D enteroids with live Salmonella Typhimurium, wild type invasive bacteria and mutant non invasive resulted in upregulation of proinflammotory cytokine IL-6 mRNA (
[0148] Although the invention has been particularly shown and described with reference to particular examples, it will be understood by those skilled in the art that various changes in the form and details may be made therein without departing from the scope of the present invention.